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SPINK9 Stimulates Metalloprotease/EGFR–Dependent
Keratinocyte Migration via Purinergic Receptor
Activation
Maria Sperrhacke1, Jan Fischer1, Zhihong Wu1, Sarah Klu¨nder1,3, Radislav Sedlacek2, Jens-Michael Schroeder1,
Ulf Meyer-Hoffert1 and Karina Reiss1
Serine protease inhibitors of the Kazal-type 9 (SPINK9) is a keratinocyte-derived cationic peptide that is found
most abundantly in the upper layers of the palmar–plantar epidermis. In vitro, the peptide displays the capacity to
inhibit specifically kallikrein-related peptidase 5 (KLK5). Here, we report that cells expressing SPINK9 secrete the
peptide constitutively. Recombinant SPINK9 (rSPINK9) provoked transactivation of the EGFR in human
keratinocytes, resulting in efficient downstream triggering of cell migration. Transactivation occurred via
functional upregulation of a disintegrin and metalloproteases (ADAMs), as evidenced by suppression with a
metalloproteinase inhibitor and an EGFR–blocking antibody. SPINK9 preparations isolated from human skin also
displayed EGFR–transactivating capacity. The classical purinergic receptor antagonists oxidized ATP and
pyridoxalphosphate-6-azophenyl-20,40,-disulfonic acid effectively suppressed EGFR transactivation by rSPINK9,
indicating that in analogy to what has recently been reported for the cationic antimicrobial peptides cathelicidin
LL-37 and bee venom melittin, purinergic receptors have an essential bridging role in promoting the upregulation
of ADAM function by the cationic peptide. SPINK9 could represent an example of how a cationic peptide may
subserve multiple and interrelated functions that contribute to the maintenance of the physical and
immunological barrier of the skin.
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INTRODUCTION
The two major families of cationic antimicrobial peptides
(AMPs) in epithelial tissues are human b-defensins and
cathelicidins (Bowdish et al., 2006; Gallo and Hooper,
2012). The parent cathelicidin molecule hCAP18 is
produced mainly by leukocytes, and is also expressed in
keratinocytes. hCAP18 must be cleaved to generate the active
AMP LL-37. This can occur through the action of leukocyte-
derived serine proteases such as proteinase 3 (Sorensen et al.,
2001). In the skin, however, cathelicidin is processed mainly
by kallikrein-related peptidase 5 (KLK5) that is constitutively
secreted by keratinocytes and present in tissues (Yamasaki
et al., 2006). This serine protease cleaves LL-37 further to
generate a wide array of smaller degradation products with
varying antimicrobial activity, which can naturally be found in
the epidermis.
LL-37 has important roles in skin physiology (Nijnik et al.,
2012; Vandamme et al., 2012). In addition to its AMP
properties, the peptide promotes IL-18 release from keratino-
cytes, is chemotactic, and provokes EGFR transsignaling
(Tjabringa et al., 2003; Tokumaru et al., 2005; Niyonsaba
et al., 2005; Carretero et al., 2008). The latter is in turn because
of the activation of shedding metalloproteinases of a disintegrin-
like and metalloproteinases (ADAMs) family, which release
EGFR ligands from their membrane anchors, allowing them to
bind to the receptor (Blobel, 2005). EGFR transactivation is
pivotally important for triggering keratinocyte proliferation and
migration. The link between ADAM17 and EGFR transsignaling
is well established. Deletion of ADAM17 mimics EGFR defi-
ciency, causing defects in hair follicle development, immature
tissue differentiation, and embryonic death (Sibilia and
Wagner, 1995; Peschon et al., 1998; Franzke et al., 2012).
A centrally important function of skin kallikreins is the
degradation of keratinocyte corneodesmosomes, enabling
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desquamation to take place. Maintenance of dermal home-
ostasis requires strict control over this process (Fischer and
Meyer-Hoffert, 2013). The lymphoepithelial Kazal-type related
inhibitor (LEKTI) encoded by serine protease inhibitor Kazal-
type 5 (spink5) assumes a pivotal role in this context (Magert
et al., 1999, 2002). The 120 kDa LEKTI precursor is cleaved
intracellularly by furin into 15 smaller fragments with highly
differing inhibitory activities. Only two of these domains (2
and 15) contain the characteristic six cysteine motif of Kazal-
type related inhibitors. Spink5 loss-of-function mutations
cause the Comel–Netherton syndrome, a severe disease
characterized by increased KLK activity and altered desqua-
mation, keratinization disorder, and skin barrier defects
(Chavanas et al., 2000).
SPINK9, also referred to as LEKTI2, shares high homology to
the LEKTI Kazal-type domains, and the 7.7 kDa peptide also
displays specific inhibitory activity against KLK5 in vitro
(Brattsand et al., 2009; Meyer-Hoffert et al., 2009). SPINK9
is detectable in the stratum granulosum (SG) and stratum
corneum (SC) of palmar and plantar skin, and is thus assumed
to participate in overall control of epidermal turnover. The
peptide shares its strongly cationic properties with AMPs such
as LL-37 and melittin.
The impetus for the present investigation stemmed from
our recent observation that melittin, the evolutionarily distant
AMP of bee venom, shared with LL-37 the remarkable
capacity of provoking ADAM–dependent EGFR transsignaling
(Niyonsaba et al., 2007; Sommer et al., 2012). If a similar
finding was made with SPINK9, this could set an example of
how cationic peptides might exert multiple and interrelated
functions in the skin. The affirmative results reported herein
further tempt speculation that a common general pattern
involving purinergic receptor activation with ensuing upregu-
lation of ADAM function underlies important responses in
mammalian cells provoked by cationic peptides of widely
differing origin.
RESULTS
Expression and secretion of SPINK9
LEKTI is localized in lamellar granules of keratinocytes and is
transported in cargo vesicles, in which it is subject to furin
processing, and is then secreted to the extracellular space in
the SG. Immunohistochemical analyses of SPINK9 expression
similarly suggested a vesicular localization in the SG and SC,
as demonstrated by a punctate staining pattern (Figure 1a and
b). When an SPINK9 expression vector with a C-terminal
enhanced green fluorescent protein (eGFP) tag and an
N-terminal hemagglutinin tag was transfected in HaCaT
keratinocytes, vesicular localization of the peptide was noted
clearly (Figure 1c). Anti-GFP immunoblot analyses of HaCaT
keratinocytes and human embryonic kidney (HEK) 293T cells
revealed double bands of approximately 37 and 41 kDa in the
pellets of both cell types and one band in the conditioned
medium (Figure 1d and e). Secretion of SPINK9 was com-
pletely abrogated in the presence of the classical secretory
pathway inhibitor brefeldin A (data not shown). Immunoblot
Lysate
kDa Mo
ck SP
INK
9-
eG
FP
Mo
ck SP
INK
9-
eG
FP
55
35
HaCaT
Supernatant Lysate
kDa M
oc
k SP
INK
9-
eG
FP Mo
ck SP
INK
9-
eG
FP
55
35
HEK 293T
Supernatant
Figure 1. Serine protease inhibitors of the Kazal-type 9 (SPINK9) is secreted as a soluble molecule. Immunohistochemical staining of SPINK9 in normal human
plantar skin. (a, b) SPINK9 is expressed in stratum granulosum and stratum corneum of plantar skin (black arrow). Bars¼50mm. (c) HaCaT cells were transfected
with enhanced green fluorescent protein (eGFP)–tagged SPINK9 and visualized under the microscope. Bar¼ 10mm. (d and e) Western blot analysis of cell lysates
and supernatants of HaCaT and human embryonic kidney (HEK) 293T cells transfected with SPINK9-eGFP. One representative immunoblot of three independent
experiments is shown, respectively.
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analyses using an anti-HA antibody did not clearly identify
SPINK9, possibly indicating that the majority of SPINK9 is
stored as a mature protein without the signal peptide.
SPINK9 provokes metalloprotease-dependent EGFR activation
Two evolutionarily distant cationic AMPs, the human cathe-
licidin LL-37 and bee venom melittin, provoke EGFR activa-
tion by upregulating ADAM–mediated shedding of EGFR
ligands. To assess whether SPINK9 might also stimulate EGFR
phosphorylation and EGFR–dependent extracellular signal–
regulated kinase 1/2 (ERK1/2) signaling, normal human epi-
dermal keratinocytes (NHEKs) were treated with increasing
concentrations of recombinant SPINK9 (rSPINK9). As shown
in Figure 2a, rSPINK9 stimulation led to a dose-dependent
increase in EGFR activation and ERK1/2 phosphorylation
(pERK1/2). Results of densitometric quantification of four
independent immunoblots are shown in Figure 2c. The
ERK1/2 activation was slightly detectable after 15 minutes
and reached a maximum between 30 minutes and 1 hour
before it decreased again (data not shown). Therefore, all
further analyses were performed after 45 minutes stimulation.
To determine whether rSPINK9–dependent phosphorylation
of ERK1/2 involved activation of a metalloprotease with the
release of EGFR ligands, human epidermal keratinocytes were
stimulated with rSPINK9 in the presence of the broad-spec-
trum metalloprotease inhibitor marimastat (MM) or the EGFR–
blocking antibody cetuximab (Cetux). As shown in Figure 2b
and d, rSPINK9–dependent phosphorylation of ERK1/2 was
completely abrogated in the presence of both inhibitors.
rSPINK9 induces migration of human keratinocytes
A major consequence that can follow from EGFR transactiva-
tion is the induction of cell migration. This has been shown to
occur following exposure of airway epithelial cells and
keratinocytes to LL-37 and melittin (Tjabringa et al., 2003;
Tokumaru et al., 2005; Niyonsaba et al., 2007; Sommer et al.,
2012). To examine whether EGFR transactivation induced by
rSPINK9 was similarly effective, in vitro scratch wound
healing assays were conducted with human keratinocytes
(Figure 3a). Indeed, stimulation with rSPINK9 at submicromo-
lar concentrations, as used previously with LL-37 and melittin,
led to a dose-dependent significant increase in cell migration
approaching that observed with the classical EGFR ligand
heparin binding-EGF (HB-EGF) (Figure 3b). To confirm that the
migratory response provoked by rSPINK9 stemmed from EGFR
transactivation, experiments were repeated in the presence or
absence of MM or Cetux. Indeed, migration induced by
rSPINK9 was efficiently blocked by both agents (Figure 3c
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Figure 2. Recombinant serine protease inhibitors of the Kazal-type 9 (rSPINK9) stimulates extracellular signal–regulated kinase 1/2 (ERK1/2) signaling via
metalloprotease and EGFR activation. (a) Normal human epidermal keratinocytes (NHEKs) were incubated with different concentrations of SPINK9 for 45 minutes.
Cell pellets were subjected to immunoblot analysis of phosphorylated EGFR (pEGFR) and phosphorylated ERK1/2 (pERK). (b) NHEKs were stimulated with SPINK9
(500 ng ml1) for 45 minutes in the presence of metalloprotease inhibitor marimastat (MM, 10mM) or cetuximab (Cetux, 10mg ml1) and analyzed for ERK1/2
activation. (c and d) Densitometric quantification of a and b. *A significant increase in ERK1/2 phosphorylation compared with non-stimulated cells (*Pp0.05;
(c) n¼ 4, (d) n¼ 6, mean±SEM). MM and Cetux significantly inhibited SPINK9–stimulated ERK1/2 activation (#Pp0.05; n¼ 6, mean±SEM).
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and d). Cell viability assays excluded that this effect was
owing to the potential cytotoxicity of the applied agents
(Supplementary Figure S1 online).
As wound healing involves cell migration and cell prolif-
eration, we additionally performed scratch assays in the
presence of proliferation inhibiting hydroxyurea (4 mM), which
however, did not affect the wound closure (data not shown).
To further analyze the contribution of rSPINK9 to keratinocyte
proliferation, cell proliferation was analyzed in comparison
with EGFR ligands amphiregulin (AREG), EGF, and HB-EGF
(Figure 3e). AREG and EGF stimulation led to a significant
increase in cell numbers, whereas HB-EGF did not show such
an effect as to be expected according to the literature (Stoll
et al., 2010; Poumay and de Rouvroit, 2012). rSPINK9
treatment did not lead to significant changes in cell
proliferation, indicating that wound closure was primarily
due to increased cell migration.
SPINK9-dependent stimulation of EGFR signaling involves P2
receptor activation
Diverse activation and cell signaling pathways have been
shown to lead to ADAM stimulation. These include activation
of G-protein coupled receptors, protein kinase C activation,
calcium influx, and activation of src kinases. Purinergic
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Figure 3. Recombinant serine protease inhibitors of the Kazal-type 9 (rSPINK9) stimulates migration of human keratinocytes. (a) Normal human epidermal
keratinocytes (NHEKs) were grown to confluence and a cell-free area was introduced. After washing, cells were mock treated or incubated with the indicated
amounts of SPINK9 for 24 hours. (c) SPINK9-stimulated migration was evaluated in the presence of the metalloprotease inhibitor marimastat (MM, 10mM) and the
EGFR–blocking antibody cetuximab (Cetux, 10mg ml1). Heparin binding-EGF (HB-EGF) (50ng ml 1) was used as control. Micrographs of one representative of
three independent experiments are shown. (b, d) Quantification of a and c. *A significant increase compared with non-stimulated samples (*Pp0.05; n¼ 3,
mean±SEM). MM and Cetux significantly inhibited SPINK9–induced migration (#Pp0.05, n¼ 3, mean±SEM). (e) Subconfluent NHEKs were stimulated with
50 ng ml1 EGFR ligands HB-EGF, amphiregulin (AREG), and EGF or with rSPINK9 (500 ng ml1) for 24 hours. Afterwards, cell proliferation was determined using
a luminescent ATP–based assay. Analyses are representative of three independent experiments. *A significant increase compared with mock-treated samples
(*Pp0.05; n¼ 6, mean±SD). (#Pp0.05, n¼ 6, mean±SD).
M Sperrhacke et al.
SPINK9 Stimulates EGFR Signaling
1648 Journal of Investigative Dermatology (2014), Volume 134
receptors have entered the scene more recently, when it
was found that they participated in EGFR transsignaling
provoked by both the human cathelicidin–derived peptide
LL-37 and melittin (Elssner et al., 2004; Tomasinsig et al.,
2008; Sommer et al., 2012). To address whether SPINK9–
dependent metalloprotease activation also involved purinergic
receptors, human keratinocytes were stimulated in the pre-
sence of the classical inhibitor of purinergic receptors
pyridoxalphosphate-6-azophenyl-20,40,-disulfonic acid (PPADS)
(Ralevic and Burnstock, 1998; Lambrecht, 2000). PPADS
effectively suppressed ERK1/2 phosphorylation (data not
shown). This finding was corrobated in experiments utiliz-
ing the irreversible specific purinergic receptor antagonist
oxidized ATP, which significantly reduced constitutive
pERK1/2 generation and inhibited the SPINK9 effects in
epithelial cells (Figure 4a, c and b, d). The functional
importance of P2 receptor signaling was evidenced by scratch
wound healing assays. Application of PPADS significantly
abolished SPINK9–induced keratinocyte migration (Figure 4e
and f).
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Figure 4. P2 receptor activation is involved in recombinant serine protease inhibitors of the Kazal-type 9 (rSPINK9)–induced EGFR signaling. (a and b) Normal
human epidermal keratinocytes (NHEKs) and human embryonic kidney (HEK) 293T cells were stimulated with rSPINK9 (500 ng ml1) in the presence and absence
of oxidized ATP (oxATP) (300mM). (c, d) Densitometric quantification of a and b. *A significant increase in extracellular signal–regulated kinase 1/2 (ERK1/2)
phosphorylation compared with non-stimulated cells. #A significant decrease compared with mock-treated rSPINK9–stimulated cells (*Pp0.05, (c) n¼ 4, (d) n¼ 6,
mean±SEM). (e) rSPINK9–stimulated migration of NHEKs is abrogated in the presence of P2 receptor inhibitor pyridoxalphosphate-6-azophenyl-20,40,-disulfonic
acid (PPADS) (200mM). Respresentative micrographs of three independent experiments are shown. (f) Quantification of three independent experiments as shown in e.
*A significant increase of migration compared with mock-treated cells (*Pp0.05). PPADS significantly inhibited rSPINK9–stimulated cell migration (#Pp0.05, n¼3,
mean±SEM). HB-EGF, heparin binding-EGF; pERK, phosphorylated ERK.
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Skin-derived SPINK9 exerts effects comparable with the
recombinant protein
SPINK9 derived from SC extracts occurs in diverse N-terminal-
truncated forms (unpublished data), of which several were
purified and tested in addition to the naturally occurring
63-amino-acid SPINK9 peptide (Figure 5a). As shown in
Figure 5b, the skin-derived natural 63-amino-acid form of
SPINK9 (nSPINK9-1) evoked EGFR transsignaling similar to
the rSPINK9 used in our study. Removal of the first and the
second amino-acid (K, KQ) reduced the EGFR–transactivating
capacity (Figure 5d and e), which was further reduced in all
shorter forms (data not shown).
DISCUSSION
The results of this investigation reveal that SPINK9 shares with
other cationic AMPs the capacity to exert multiple indepen-
dent functions. The peptide was originally detected in anti-
microbial active fractions (unpublished data), but as with
many other AMPs, the bactericidal mechanism of action still
needs to be elucidated.
The isolated peptide was designated SPINK9 because of its
homology with the Kazal domain contained within LEKTI. This
domain had been known to possess KLK5–inhibiting proper-
ties, and these were then also found for SPINK9 (Brattsand
et al., 2009; Meyer-Hoffert et al., 2009). The protease-
inhibiting properties have been characterized and the
reactive loop has been defined to residues 48 and 49 of
SPINK9 (Brannstrom et al., 2012).
The present study has identified an additional biological
activity of SPINK9: the capacity to trigger EGFR transsig-
naling in keratinocytes, which in turn stimulates cell migra-
tion. In this regard, SPINK9 mimics the action of two
evolutionarily distant cationic AMPs, human cathelicidin
LL-37 and bee venom melittin. The combination of diverse
biological activities united in SPINK9 is unique and provokes
speculation on the biological role the peptide may have,
particularly with regard to the regulation of LL-37 homeostasis
(Figure 6).
The parent cathelicidin hCAP18 can be transported to the
skin by leukocytes or produced locally by keratinocytes.
Biologically active LL-37 in the epidermis can be generated
through its processing by the action of leukocyte-derived
proteases or by naturally occurring tissue proteases, in
particular by KLK5. After its generation, LL-37 will be further
degraded by KLK5 and KLK7, which results in the generation
of peptides with varying length and antimicrobial activity that
have been detected in human epidermis (Yamasaki et al.,
2006).
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Figure 5. Different truncated forms of skin-derived serine protease inhibitors of the Kazal-type 9 (SPINK9) induce extracellular signal–regulated kinase
(ERK) activation. (a) Overview of different SPINK9 forms, which occur in human skin. (b) Stimulation with the 63-amino-acid naturally occurring peptide
(nSPINK9-1) leads to ERK1/2 activation in normal human epidermal keratinocytes (NHEKs) similar to the recombinant SPINK9 (rSPINK9) used in our study.
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In analogy to LEKTI, SPINK9 can thus be expected to be
involved in maintaining overall homeostasis of LL-37 and in
sustaining the balance of LL-37-mediated functions. This may
become particularly relevant when hCAP18 levels exceed
critical limits. Preliminary data indicate that release of SPINK9
is increased in activated keratinocytes, and a study is under-
way to analyze its expression in wound epithelial tissue with
particular regard to LEKTI expression.
The phenomenon of EGFR transsignaling provoked by LL-37
was first reported in airway epithelial cells (Tjabringa et al.,
2003). This event was subsequently shown to stimulate the
migration of keratinocytes (Tokumaru et al., 2005; Niyonsaba
et al., 2007) and other cell types (von Haussen et al., 2008;
Shaykhiev et al., 2010), leading to the conclusion that LL-37
may have a role in promoting wound closure. The potential
importance of AMPs for wound healing has been confirmed
by in vivo studies demonstrating that adenoviral transfer of
LL-37 in excisional wounds improved re-epithelialization in
mice (Carretero et al., 2008).
Stimulation of cell proliferation and migration through
EGFR activation are known to be intercorrelated processes,
and the expected mitogenic action of LL-37 has been demon-
strated in fibroblasts (Tomasinsig et al., 2008) and keratino-
cytes (Niyonsaba et al., 2007). Analogous findings have
recently been made with melittin, where EGFR transsignal-
ing was shown to trigger proliferation and migration of human
keratinocytes (Sommer et al., 2012).
SPINK9 is now the third cationic peptide for which EGFR–
transactivating properties are reported. The experimental
approaches underlying this conclusion are established. EGFR
transsignaling occurs because of functional upregulation of
cellular metalloproteinases of the ADAM family, which cleave
and release EGFR ligands, in particular HB-EGF from their
membrane anchors, enabling them to bind to the receptor
(Maretzky et al., 2011). The ensuing ERK1/2 phosphorylation is
consequently abrogated by metalloprotease inhibitors and by
the monoclonal antibody that blocks the EGFR. The same
agents suppress cell migration. All these findings were made
when SPINK9 was used as the stimulus, at the same submicro-
molar concentrations as had previously been observed with
LL-37-mediated EGFR transsignaling (Tokumaru et al., 2005).
Thus, the remarkable conclusion appears inescapable that the
protease inhibitor itself has EGFR–transactivating properties
similar to those possessed by the very molecule whose fate it
controls.
A direct SPINK9–EGFR interaction as has been previously
shown for SPINK1 (Ozaki et al., 2009), seems unlikely since
co-immunoprecipitation experiments yielded negative results
(data not shown). The micromolar concentrations of SPINK9
that are required to provoke the reported effects also speak
against a ligand–receptor interaction.
It might be speculated that SPINK9 exerts even additional
functions besides EGFR activation, which are important
for wound healing. The porcine cathelicidin PR-39 has
been found to modulate cell surface heparan sulfate proteo-
glycan expression, thus triggering cellular responses to
heparin-binding growth factors (Gallo et al., 1994). Whether
this could also be true for SPINK9 needs to be addressed in
further studies.
In our previous study conducted with melittin, we presented
evidence that purinergic receptors have an essential bridging
role in the AMP–ADAM/EGFR stimulatory axis.
This result was consistent with studies that had indicated
involvement of purinergic receptors in mediating the EGFR–
transsignaling effects of LL-37 (Elssner et al., 2004; Tomasinsig
et al., 2008). In the present investigation, it was similarly
found that EGFR transsignaling provoked by SPINK9 was
effectively suppressed by the purinergic receptor inhibitors
tested: PPADS and the highly specific oxidized ATP. The
emerging tentative conclusion is that diverse cationic peptides
may generally be able to stimulate purinergic receptors, which
can lead to downstream enhancement of ADAM function.
How cationic peptides should activate purinergic receptors
requires further study. ATP efflux occurring in cells exposed to
LL-37 has been proposed to be directly responsible (Elssner
et al., 2004). In that investigation, however, the peptide was
used at cytotoxic doses, two orders of magnitude above those
that provoked EGFR transsignaling by LL-37 (Tokumaru et al.,
2005), melittin (Sommer et al., 2012), and as shown here, by
SPINK9. In the melittin study, we observed that EGFR trans-
signaling was reduced in the presence of ATP–hydrolyzing
agents. However, the inability to fully inhibit the effect led to
the suspicion that additional mechanisms were operative in
purinergic receptor triggering. In the present investigation, no
significant ATP release could be detected, and no reduction
in EGFR transsignaling was noted despite the presence of
ATPases (data not shown). Thus, although all studies agree that
purinergic receptor signaling relays the cellular effects of
AMPs to ADAMs, a fully satisfactory explanation to account
for the phenomenon is not really at hand (Reiss and Bhakdi,
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2012). A possibility that may be worth examining is that AMPs
unspecifically activate purinergic receptors simply on the basis
of their cationic nature.
Links between purinergic receptor signaling and ADAM
activation have been reported in a relatively small number of
studies from several laboratories. Shedding of L-selectin from
human (Jamieson et al., 1996; Gu et al., 1998; Elliott et al.,
2005) and CD27 from mouse lymphocytes (Moon et al., 2006)
as well as CD23 from human dendritic cells (Sluyter and
Wiley, 2002) provided first examples. More recently, puriner-
gic receptors were demonstrated to trigger ADAM–dependent
processing of the amyloid precursor protein (Camden et al.,
2005; Delarasse et al., 2011) and to mediate ADAM–
dependent EGFR transsignaling in human salivary gland cells
(Ratchford et al., 2010). The findings we have made with
cationic peptides relate well with all these findings, and in
particular with the data on EGFR transsignaling presented by
Ratchford et al. (2010).
In sum, the possibility emerges that SPINK9 could fulfill
surprisingly diverse biological functions in the skin. It may
participate in the control of kallikrein and consequently of
LL-37 homeostasis. Here, we would like to direct attention to
the finding that cationic peptides, in addition to their potential
antimicrobial action, may further influence cell proliferation
and wound closure through their capacity to trigger ADAM–
mediated transsignaling of the EGFR.
MATERIALS AND METHODS
Reagents and antibodies
The EGFR function–blocking antibody Cetux (C225) was purchased
from Merck (Darmstadt, Germany), anti-GFP (clone 7.1þ 13.1) from
Roche (Mannheim, Germany), and anti-phospho-ERK1/2 (clone
D13.14.4E) and anti-ERK1/2 (clone L34F12) from Cell Signaling
(Boston, MA). The polyclonal goat anti-human SPINK9 was produced
as described previously (Meyer-Hoffert et al., 2009). PPADS and
oxidized ATP were obtained from Sigma (Taufkirchen, Germany).
MM was purchased from Tocris (Minneapolis, MN). Stock solutions of
most stimuli/inhibitors were prepared with sterile water. MM was
dissolved in DMSO. Water or DMSO was diluted in the media to
serve as mock controls in the respective experiments.
Cell culture
HaCaT and HEK 293T cells were grown in DMEM supplemented
with 100 U ml 1 penicillin, 100mg ml 1 streptomycin (PAA,
Freiburg, Germany), and 10% fetal calf serum. NHEKs (PromoCell,
Heidelberg, Germany) were grown in the keratinocyte growth
medium 2 (PromoCell) with 1 supplements, 0.06 mM Ca2þ ,
100 U ml 1 penicillin, and 100mg ml 1 streptomycin (PAA). Cells
were cultured at 37 1C and 5% CO2 under standard tissue culture
conditions.
Production of rSPINK9
Expression of fusion protein was performed as described before
(Meyer-Hoffert et al., 2009). After cleavage of the fusion protein
with enterokinase, the pET32a tag and SPINK9 were separated using
cation exchange chromatography containing 20 mM Tris-HCl buffer
(pH 8.0) with a gradient to the elution buffer (20 mM Tris-HCl buffer
with 1 M NaCl, pH 8.0). Final separation was carried out with an
analytical reversed-phase C18 column as described elsewhere
(Meyer-Hoffert et al., 2009).
Purification of human SPINK9 from SC extract
Acidic extracts from healthy persons’ SC were dialyzed (cutoff: 3 kDa)
against neutral buffer and applied to a heparin–sepharose cartridge.
Bound proteins were further separated by wide-pore reversed-phase
chromatography (C8) followed by cation exchange chromatography.
The last separation step was carried out using an analytical C18
column. For details see Meyer-Hoffert et al. (2009).
Cloning of expression vector
The expression vector for SPINK9-eGFP was cloned by using full-
length cDNA of human SPINK9. The cDNA was tagged with an
N-terminal hemagglutinin tag and a C-terminal eGFP tag in three
steps. First, the cDNA was amplified with the forward primer (50-TAT
CTCGAGGCCACCATGTACCCATACGATGTTCCAGATTACGCTAGA
GCAACAGCCATAGTCCTAC-30 and the reversed primer (50-CTCC
TCGCCCTTGCTCACTGGTGGACATTTTCCAAAATGTACAAAT-30).
The forward primer includes the N-terminal hemagglutinin sequence;
the reversed primer includes a sequence overlapping with eGFP. In a
second step, eGFP was amplified with the forward primer (50-GTACA
TTTTGGAAAATGTCCACCAGTGAGCAAGGGCGAGGAG-30) and
the reversed primer (50-TATGGATCCTCAAGCTGATCTGAGTCCGG
ACTTG-30). The forward primer contains the N-terminal overlap of
spink9. Finally, an overlap PCR with these two amplificates was
performed to fuse spink9 with eGFP. The resulting PCR product was
cloned into the pcDNA3.1 mammalian expression vector via XhoI
and BamHI. The sequence of tagged SPINK9 was verified by
sequencing (Seqlab, Go¨ttingen, Germany).
Transfection
HEK 293T cells and HaCaT cells were grown to 80–90% confluence
in a 12-well plate and transfected with 1mg SPINK9-eGFP using 3ml
TurboFect (Thermo Scientific, Waltham, MA) in DMEM without
supplements. After 6 hours, the medium was exchanged with DMEM
supplemented with fetal calf serum and penicillin/streptomycin. After
24 hours, the medium was changed to DMEM without supplements to
stimulate the cells.
IHC and ICC
Immunohistochemical staining of paraffin-embedded tissue was
performed as described previously (Meyer-Hoffert et al., 2009). The
slides were deparaffinized, rehydrated, and heated in 0.01 M citrate
buffer (pH 6.0). Afterwards, they were blocked by using 1% BSA and
1 Roti-ImmunoBlock (Carl-Roth, Karlsruhe, Germany). Antibody
staining was performed overnight at 4 1C with affinity-purified
polyclonal goat anti-SPINK9 antibody (1:100 dilutions). The
secondary antibody was a biotinylated horse anti-goat IgG (1:500;
Biologo, Kronshagen, Germany). For visualization, a combination of
Alkaline Phosphatase Standard, Vectastain ABC Kit (Biologo) and
Alkaline Phosphatase Substrate Kit I, Vectastain ABC Kit (Biologo) was
used and costained with hematoxylin (Merck).
HaCaT cells transfected with eGFP-SPINK9 were fixed with 3%
paraformaldehyde, embedded in Mowiol (Calbiochem, Darmstadt,
Germany) supplemented with 20 mg ml 1 DABCO (Carl-Roth) and
1mg ml 1 4’,6-diamidino-2-phenylindole (Sigma-Aldrich), and ana-
lyzed by fluorescence microscopy.
M Sperrhacke et al.
SPINK9 Stimulates EGFR Signaling
1652 Journal of Investigative Dermatology (2014), Volume 134
Immunoblot
Cells were lysed using lysis buffer (1% Triton X-100, 5 mM Tris, 1 mM
EGTA, 250 mM saccharose, pH 7.4). Lysates were clarified from
insoluble material by centrifugation. Protein concentration was
measured using Bradford reagent (Thermo Fisher Scientific). Equal
amounts of protein were used. The proteins were separated by SDS-
PAGE under reducing conditions and transferred onto PVDF mem-
brane (0.45mm; Roth). The secondary antibodies were coupled to
horseradish peroxidase (Dianova, Hamburg, Germany). Immunode-
tection was performed via chemiluminescence (ECL Select; GE
Healthcare, Freiburg, Germany). Signals were recorded by a lumi-
nescent image analyzer (Fusion-FX7; PEQLAB, Erlangen, Germany)
and analyzed with image analyzer software (BIO-1D; PEQLAB). To
generate the control blots for expression of ERK1/2 and EGFR, western
blot analysis were incubated in the stripping reagent (100 mM
2-mercaptoethanol, 2% (w v 1) SDS, 62.5 mM Tris-HCl (pH 6.7)) at
55 1C for 30 minutes and then reprobed with anti-ERK1/2 or EGFR
antibody, respectively. Densitometric quantification shows the
amount of ERK1/2 phosphorylation relative to total ERK1/2. Values
are normalized to mock-treated cells.
In vitro wound healing
NHEKs were seeded in 6-well plates (Sarstedt, Nu¨mbrecht, Germany)
and grown until they reached confluence (48 hours). A cell-free area
was introduced by scraping the monolayer with a toothpick. Directly
after scraping the monolayer, cells were washed once with phos-
phate-buffered saline to remove cell debris. For stimulation experi-
ments, keratinocyte growth medium 2 without supplements, Ca2þ ,
and antibiotics containing SPINK9 or HB-EGF was added and cells
were photographed. For stimulation in the presence of inhibitors, the
inhibitors were preincubated for 15 minutes before SPINK9 was
added. Cells were again photographed 24 hours after stimulation
using an inverted phase-contrast microscope (Zeiss, Oberkochen,
Germany). The cell-free area was quantified using AxioVision (Zeiss)
before and after stimulation, respectively, and percentage of migra-
tion was calculated.
Cell proliferation and viability assay
CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison,
WI) was used to determine the number of viable cells based on
quantitation of ATP. To determine cell proliferation, 8,500 cells
per well (subconfluent) were seeded in a 48-well plate and stimulated
with HB-EGF, AREG, and EGF (all 50 ng ml 1) or SPINK9
(500 ng ml 1) for 24 hours in keratinocyte growth medium 2 without
supplements.
To exclude cytotoxic effects of MM or Cetux, cells were seeded in a
48-well plate and grown until confluence for 48 hours to mimic
scratch assay conditions. Then, they were treated with MM (10mM) or
Cetux (10mg ml 1) for 24 hours in keratinocyte growth medium 2
without supplements. The number of viable cells was determined by
the addition of CellTiter-Glo Reagent (Promega) according to the
manufacturer’s instruction followed by measurement of luminescence
(Biotek FLx800 reader, Bad Friedrichshall, Germany).
Statistical analysis
All values are expressed as means±SEM unless otherwise stated. The
standard error values indicate the variation between mean values
obtained from at least three independent experiments or as indicated.
Variance analysis was performed with one-way analysis of variance
using SigmaStat 3.1 software (SYSSTAT; Erkrath, Germany). Multiple
parametric statistical comparisons between experimental groups
versus a control group and pairwise multiple comparison procedures
were performed with Bonferroni test. P-values o0.05 were classified
as statistically significant.
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